FDA Announces Recall of Dobutamine Injection by Hospira: AttorneyOne Monitor and Keep Consumers Informed

On May 15, the FDA announced that one lot of Dobutamine Injection USP, 250 mg/20 mL single-dose fliptop vial, by Hospira, is recalled due to visible particulates. In light of this news, AttorneyOne, a recognized authority on law, updated the website providing detailed information to consumers.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friendRepost This
Dobutamine Injection by Hospira: Recall

Dobutamine Injection by Hospira: Recall

we are determined to keep an eye on FDA announcements concerning Dobutamine Injection and inform the public

San Diego, CA (PRWEB) May 19, 2014

AttorneyOne.com, a recognized authority on law, update the website daily regarding all the latest information from the FDA on safety alerts for Dobutamine Injection.

The FDA announced on May 15, that one lot of Dobutamine Injection USP, 250 mg/20 mL single-dose fliptop vial, by Hospira, is recalled due to a confirmed customer report of discolored solution. The Lot is 27-352-DK and review of the complaint revealed a chip in the glass at the neck of the vial as well as glass particulate within the solution.

Injection of particulate matter may cause phlebitis, local inflammation, and/or low level allergic response. Moreover, contaminated solution may cause sepsis, bacteremia, septic shock and endocarditis, and death.

Taking into consideration the latest developments, AttorneyOne.com monitor daily and update the website providing accurate information on all relevant FDA safety alerts. Sean Burke, director of Media Relations at AttorneyOne.com, adds “we are determined to keep an eye on FDA announcements concerning Dobutamine Injection and inform the public. For that reason", he continues, "our focus should squarely fall on investigating these safety alerts and getting the word out.”

The US FDA recommends “Anyone with an existing inventory should immediately stop use and quarantine any affected product. In addition, customers should inform potential users of this product in their organizations of this notification.” And the Agency adds “Dobutamine should be considered a potent drug and potentially irritating to eyes and respiratory tract. Users should avoid liquid aerosol generation and skin contact.”

AttorneyOne.com has further information on Dobutamine Injection at the website including latest major drug and medical products law news.

Headquartered in San Diego, CA Attorney One was founded in 2004 and is not a law firm. They offer a nationwide legal service which helps consumers find the best representation for their legal needs. You can learn more about Attorney One at our website http://www.attorneyone.com. You can also find us on Facebook at http://www.facebook.com/AttorneyOne. Checkout earlier news from us at http://www.prweb.com/releases/2014/05/prweb11859128.htm